Decision on optimal combinatorial Therapies in IMIDS using Systems Approaches

Project Overview

DoCTIS is an EU-funded translational project aimed at addressing the urgent need to discover effective therapeutic strategies for immune-mediated inflammatory diseases.

Partners

Biomedical research partners from five different European countries as well as from the United States of America are collaborating toward this.

Work Packages

The DoCTIS project is structured in nine different work packages, involving animal model, patient, systems biology and clinical evaluation stages.

ABOUT DocTIS

DoCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches”. DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis. Through the generation of high volumes of data using of modern high-throughput technologies on samples from well-characterized IMID patients, and the use of advanced systems biology analytical approaches, we aim to identify therapeutic combinations that are much more efficacious and safer than current single-drug approaches.

MEDIA CENTER


Follow the most recent activity generated from the DoCTIS project.

News

See DoCTIS in the media and published work derived from the project.

Events

Calendar of future and past events associated to the DoCTIS project.

Patients

If you are a patient suffering from an IMID, click here to know more on how the research at the DoCTIS project is working to help you.

Amgen to advance KRAS drug combination after improved results in colon cancer https://www.biopharmadive.com/news/amgen-lumakras-colorectal-cancer-combination/606700/ via @BioPharmaDive

Despite major advances in the molecular and cellular characterization of common diseases, there has been a steady decline of new effective therapies. Join us October 7th on “Combination therapies in common diseases: clinical and translational challenges”.👉https://doctis.eu/doctis-symposium-event/

2

🔴#SavetheDate On October 7th we have organised a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. Sponsored by @IMIDomics. Register now on👉 https://attendee.gotowebinar.com/register/35653181604036875

💻Read all about it 👉 https://doctis.eu/doctis-symposium-event/

🔴#SavetheDate On October 7th we have organised a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. Further information coming soon.

Mark your calendars!

2

DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs). More on👉https://doctis.eu/ #AboutDOCTIS

Load More…